1
SCHEDULE 14A INFORMATION
PROXY STATEMENT PURSUANT TO SECTION 14(A) OF
THE SECURITIES EXCHANGE ACT OF 1934
Filed by the Registrant [X]
Filed by a Party other than the Registrant [ ]
Check the appropriate box:
[ ] Preliminary Proxy Statement
[ ] Confidential, for Use of the Commission Only
(as permitted by Rule 14a-6(e)(2))
[ ] Definitive Proxy Statement
[X] Definitive Additional Materials
[ ] Soliciting Material Pursuant to sec.240.14a-11(c) or sec.240.14a-12
LIDAK PHARMACEUTICALS
- --------------------------------------------------------------------------------
(Name of Registrant as Specified In Its Charter)
- --------------------------------------------------------------------------------
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check the appropriate box):
/X/ No fee required.
/ / Fee computed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11.
(1) Title of each class of securities to which transaction applies:
(2) Aggregate number of securities to which transaction applies:
(3) Per unit price or other underlying value of transaction computed
pursuant to Exchange Act Rule 0-11 (Set forth the amount on which the
filing fee is calculated and state how it was determined):
(4) Proposed maximum aggregate value of transaction:
(5) Total fee paid:
/ / Fee paid previously with preliminary materials.
/ / Check box if any part of the fee is offset as provided by Exchange Act Rule
0-11(a)(2) and identify the filing for which the offsetting fee was paid
previously. Identify the previous filing by registration statement number,
or the Form or Schedule and the date of its filing.
(1) Amount Previously Paid:
(2) Form, Schedule or Registration Statement No.:
(3) Filing Party:
(4) Date Filed:
2
FOURTH AMENDMENT TO AMENDED AND RESTATED
BYLAWS OF LIDAK PHARMACEUTICALS
March 14, 1998
Article 2 - "Meetings of Shareholders," Section 2.1.2 of the Amended and
Restated Bylaws of LIDAK Pharmaceuticals, a California corporation, is hereby
amended and restated as follows:
"2.1.2 (a) The annual meeting of shareholders shall be held each year
on a date and at a time fixed by the Board of Directors. At each annual
meeting, (i) directors shall be elected from the persons who are nominated
in accordance with the procedures set forth in paragraph (b) below and (ii)
any proper business shall be conducted which has been submitted in
accordance with the procedures set forth in paragraph (b) below.
(b) Only proper business which has been submitted in accordance with
the following procedures shall be conducted at the annual meeting.
Submissions of nominations of persons for election as directors or other
proper business to be conducted at the annual meeting may be made at such
meeting by or at the direction of the Board of Directors, by any committee
or persons appointed by the Board of Directors or by any shareholder of the
corporation who complies with the notice procedures set forth in this
paragraph. Such submissions of proper business by any shareholder shall be
made pursuant to timely notice in writing to the Secretary of the
corporation. To be timely, a shareholder's notice shall be delivered to, or
mailed and received at, the principal executive offices of the corporation
not less than 10 days prior to the annual meeting. Such shareholder's
notice to the Secretary shall set forth (i) a description of the proper
business submitted for consideration at the annual meeting, (ii) the name
and record address of the stockholder giving the notice, (iii) the class
and number of shares of capital stock of the corporation which are
beneficially owned by the stockholder, and (iv) if such business involves
the nomination of a person for election as a director, the name, age,
business and residence addresses and principal occupation of such person.
No proper business shall be conducted at the annual meeting unless
submitted in accordance with the procedures set forth herein. The officer
of the corporation presiding at an annual meeting shall, if the facts
warrant, determine and declare to the meeting that a submission of a proper
nomination or proper business was not made in accordance with the foregoing
procedure, and if he should so determine, he shall so declare to the
meeting and the defective submission shall be disregarded."
All other provisions of the Amended and Restated Bylaws remain unchanged and in
full force and effect.
3
DATE: MARCH 16, 1998 CONTACT: JEFFERY B. WEINRESS
VICE PRESIDENT & CFO
LIDAK PHARMACEUTICALS
RELEASE DATE: IMMEDIATE (619) 558-0364, EXT. 242
LIDAK PHARMACEUTICALS ANNOUNCES
BYLAW AMENDMENT REGARDING PROPER
SUBMISSION OF BUSINESS TO ANNUAL MEETING
LA JOLLA, CALIFORNIA - March 16, 1998 -- LIDAK Pharmaceuticals (NASDAQ NM:
LDAKA) announced today that its Board of Directors has adopted unanimously an
amendment to the Company's Bylaws, to provide that any shareholder seeking to
nominate a candidate for election as a director at the Company's annual meeting
or to submit other proper business to be conducted at the annual meeting must
deliver timely advance written notice of the nomination or submission to the
Secretary of the Company. To be timely, a shareholder's notice must be delivered
to, or mailed and received at, the Company's executive offices not less than 10
days prior to the annual meeting. A shareholder's notice must set forth (i) a
description of the proper business submitted for consideration at the annual
meeting, (ii) the name and record address of the shareholder giving notice,
(iii) the class and number of shares of capital stock of the Company which are
beneficially owned by the shareholder, and (iv) if the business involves the
nomination of a person for election as a director, the name, age, business and
residence address and principal occupation of such person.
The 1998 Annual Meeting of Shareholders of LIDAK Pharmaceuticals will be
held on April 18, 1998, so to be timely notice must be received at the Company
by April 8, 1998.
William N. Jenkins, Chairman of the Board, stated, "We have adopted this
Bylaw amendment to allow shareholders enough time to nominate candidates or to
submit proper business to be conducted at the annual meeting, while at the same
time providing the Board sufficient opportunity to evaluate the merits of any
proposal and assure an orderly and productive annual meeting of shareholders."
LIDAK Pharmaceuticals is developing therapeutic products designed to treat
virally caused diseases, allergies and asthma, inflammatory disorders and
cancer.
# # #
The information contained in this press release, including any forward
looking statements contained herein, should be reviewed in conjunction with the
Company's Annual Report on Form 10-K and other publicly available information
regarding the Company, copies of which are available from the Company upon
request. Such publicly available information sets forth many risks and
uncertainties related to the Company's business and such statements, including
risks and uncertainties related to drug development and clinical trials. Final
review decisions made by the FDA and other regulatory agencies concerning
clinical trial results are unpredictable and outside of the influence and/or
control of the Company.